ReviewJID innovations : skin science from molecules to population health2026
Autoantibodies as biomarkers of cancer risk in dermatomyositis.
Review in JID innovations : skin science from molecules to population health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: breast cancer presenting as dermatomyositis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Dermatomyositis (DM) is a cardinal example of an autoimmune rheumatic disease associated with an increased risk of cancer. Research over the past 2 decades highlights that specific DM autoantibodies are associated with overall risk of cancer emergence, with recent research identifying co-occurring "add-on" autoantibodies that appear to attenuate malignancy risk. Although the mechanism of this association remains unclear, a leading hypothesis is cancer-induced autoimmunity in which physiologic cancer immunosurveillance leads to autoimmune disease in the appropriate host. This review synthesizes our current understanding of autoantibodies and DM-associated malignancy with a focus on helping to individualize cancer risk stratification and allow selection of the appropriate aggressive and timely cancer screening modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.